KalVista Pharmaceuticals’ (KALV) Buy Rating Reaffirmed at Jones Trading
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading in a report issued on Wednesday,Benzinga reports. They presently have a $30.00 price target on the specialty pharmaceutical company’s stock. Jones Trading’s target price suggests a potential upside of 143.11% from the stock’s previous close. Other equities […]
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading in a report issued on Wednesday,Benzinga reports. They presently have a $30.00 price target on the specialty pharmaceutical company’s stock. Jones Trading’s target price suggests a potential upside of 143.11% from the stock’s previous close. Other equities […]
